VALBIOTIS SAS (ALVAL.PA)
FR0013254851 - Common Stock
Overall ALVAL gets a fundamental rating of 3 out of 10. We evaluated ALVAL against 73 industry peers in the Biotechnology industry. ALVAL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALVAL shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year ALVAL has reported negative net income.
ALVAL had a negative operating cash flow in the past year.
ALVAL had negative earnings in each of the past 5 years.
In the past 5 years ALVAL reported 4 times negative operating cash flow.
1.2 Ratios
ALVAL has a Return On Assets of -22.13%. This is comparable to the rest of the industry: ALVAL outperforms 54.41% of its industry peers.
ALVAL has a Return On Equity of -37.61%. This is comparable to the rest of the industry: ALVAL outperforms 58.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.13% | ||
| ROE | -37.61% | ||
| ROIC | N/A |
ROA(3y)-32.59%
ROA(5y)-30.5%
ROE(3y)-63.5%
ROE(5y)-62.14%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALVAL's Gross Margin of 48.69% is fine compared to the rest of the industry. ALVAL outperforms 66.18% of its industry peers.
In the last couple of years the Gross Margin of ALVAL has declined.
ALVAL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.69% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.78%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ALVAL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALVAL has more shares outstanding
The number of shares outstanding for ALVAL has been increased compared to 5 years ago.
ALVAL has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.43, we must say that ALVAL is in the distress zone and has some risk of bankruptcy.
ALVAL has a better Altman-Z score (1.43) than 61.76% of its industry peers.
ALVAL has a Debt/Equity ratio of 0.24. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.24, ALVAL is doing good in the industry, outperforming 61.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.43 |
ROIC/WACCN/A
WACC8.06%
2.3 Liquidity
A Current Ratio of 3.49 indicates that ALVAL has no problem at all paying its short term obligations.
ALVAL has a Current ratio of 3.49. This is in the better half of the industry: ALVAL outperforms 72.06% of its industry peers.
A Quick Ratio of 3.38 indicates that ALVAL has no problem at all paying its short term obligations.
With a decent Quick ratio value of 3.38, ALVAL is doing good in the industry, outperforming 73.53% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.49 | ||
| Quick Ratio | 3.38 |
3. Growth
3.1 Past
ALVAL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.80%, which is quite impressive.
ALVAL shows a strong growth in Revenue. In the last year, the Revenue has grown by 498.99%.
The Revenue has been growing by 126.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)50.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.91%
Revenue 1Y (TTM)498.99%
Revenue growth 3Y15.25%
Revenue growth 5Y126.73%
Sales Q2Q%228%
3.2 Future
Based on estimates for the next years, ALVAL will show a very strong growth in Earnings Per Share. The EPS will grow by 20.77% on average per year.
The Revenue is expected to grow by 26.00% on average over the next years. This is a very strong growth
EPS Next Y-43.07%
EPS Next 2Y20.02%
EPS Next 3Y20.77%
EPS Next 5YN/A
Revenue Next Year-85.43%
Revenue Next 2Y-2.9%
Revenue Next 3Y26%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
ALVAL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALVAL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ALVAL's earnings are expected to grow with 20.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.02%
EPS Next 3Y20.77%
5. Dividend
5.1 Amount
No dividends for ALVAL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VALBIOTIS SAS
EPA:ALVAL (9/18/2024, 7:00:00 PM)
1.332
+0.01 (+0.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap21.02M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.13% | ||
| ROE | -37.61% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.69% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.14
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.49 | ||
| Quick Ratio | 3.38 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)50.8%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-43.07%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)498.99%
Revenue growth 3Y15.25%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y